
    
      This phase III randomized clinical trial was designed to compare metronomic Cyclophosphamide
      with standard Doxorubicin for the first-line treatment of elderly cancer patients with
      advanced inoperable or metastatic STS:

      i) ARM A (experimental): Metronomic Cyclophosphamide ii) ARM B (control): Doxorubicin up to
      six cycles
    
  